Pertzye market sees growth opportunities through 2030

The Business Research Company says the Pertzye market is being lifted by rising chronic pancreatitis, broader use of personalized medicine, and more digestive disorder diagnoses. North America led the market in 2025, while Asia-Pacific is projected to grow fastest through the forecast period.

Why it matters: - Pertzye is tied to treatment for exocrine pancreatic insufficiency, a condition that affects digestion and nutrient absorption. - The market’s growth is linked to rising disease prevalence, more targeted treatment approaches, and broader adoption of enzyme replacement therapies. - The report points to opportunities in high-strength formulations, buffering technologies, and long-term management programs.

What happened: - The Business Research Company published a new global report on the Pertzye market, covering market size, trends, and forecasts for 2026-2035. - The report says the market has grown steadily in recent years and is expected to keep expanding through 2030 and beyond. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Pertzye contains pancrelipase, a combination of lipase, protease, and amylase enzymes. - The drug is prescribed for exocrine pancreatic insufficiency, where the pancreas does not produce enough enzymes for digestion. - Pertzye uses a bicarbonate-buffered enteric coating to help deliver enzymes to the small intestine. - The report cites chronic pancreatitis as a major growth driver because the disease can cause lasting pancreatic damage and digestive complications. - A population-based study published in August 2023 in the World Journal of Gastroenterology reported a point prevalence of chronic pancreatitis of 45.52 per 100,000 people in Sichuan Province, China. - The report says personalized medicine is supporting demand for targeted enzyme replacement therapy. - A February 2024 report from the Personalized Medicine Coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Rising digestive disorders are also increasing demand for treatments tied to pancreatic insufficiency. - The UK-based IBD Registry said in December 2023 that its membership had grown to more than 5,300 people with inflammatory bowel disease by 2023, up by more than 3,000 from 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report includes links for a free sample and the full market report.

Between the lines: - The market narrative is less about one drug and more about a broader shift toward precision treatment for chronic digestive disease. - Growth appears tied to both better diagnosis and longer-term management, which can expand use even when disease prevalence changes slowly. - Regional growth differences suggest mature markets will remain important, but faster adoption may come from improving healthcare access in emerging markets.

What's next: - The report expects demand to rise as healthcare providers expand use of enzyme replacement therapies and higher-strength formulations. - Continued innovation in drug delivery coatings and patient adherence tools could shape the market’s next phase. - Ongoing monitoring of chronic pancreatitis, EPI, and other digestive disorders will likely influence future demand.